Q2 Earnings Forecast for Korro Bio Issued By HC Wainwright

Korro Bio, Inc. (NASDAQ:KRRO) – HC Wainwright upped their Q2 2026 EPS estimates for Korro Bio in a note issued to investors on Tuesday, May 19th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($1.35) per share for the quarter, up from their previous estimate of ($1.85). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($5.63) per share. HC Wainwright also issued estimates for Korro Bio’s Q3 2026 earnings at ($1.38) EPS, Q4 2026 earnings at ($1.44) EPS and FY2026 earnings at ($5.81) EPS.

Korro Bio (NASDAQ:KRRO) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.09). Korro Bio had a negative return on equity of 117.86% and a negative net margin of 1,834.48%.

Other equities analysts have also issued reports about the stock. Wall Street Zen raised shares of Korro Bio from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Korro Bio in a report on Wednesday, April 8th. Clear Str raised shares of Korro Bio from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 18th. Cantor Fitzgerald boosted their price objective on shares of Korro Bio from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Friday, March 13th. Finally, Raymond James Financial raised shares of Korro Bio from a “market perform” rating to an “outperform” rating and set a $23.00 price objective on the stock in a report on Friday, March 13th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $16.71.

Korro Bio Trading Up 9.4%

NASDAQ KRRO opened at $10.01 on Thursday. The firm’s fifty day simple moving average is $12.26 and its two-hundred day simple moving average is $11.87. Korro Bio has a 12-month low of $5.20 and a 12-month high of $55.89. The firm has a market capitalization of $144.34 million, a P/E ratio of -0.86 and a beta of 3.07.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KRRO. Geode Capital Management LLC lifted its position in Korro Bio by 10.8% during the second quarter. Geode Capital Management LLC now owns 155,387 shares of the company’s stock valued at $1,941,000 after purchasing an additional 15,166 shares during the period. Raymond James Financial Inc. lifted its position in Korro Bio by 357.6% during the second quarter. Raymond James Financial Inc. now owns 83,392 shares of the company’s stock valued at $1,042,000 after purchasing an additional 65,170 shares during the period. Bank of America Corp DE lifted its position in Korro Bio by 520.0% during the second quarter. Bank of America Corp DE now owns 28,156 shares of the company’s stock valued at $352,000 after purchasing an additional 23,615 shares during the period. Emerald Mutual Fund Advisers Trust acquired a new position in Korro Bio during the third quarter valued at $2,821,000. Finally, Wealth Forward LLC acquired a new position in Korro Bio during the third quarter valued at $240,000. 13.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, major shareholder Paul Edward Walker acquired 207,100 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were purchased at an average cost of $11.11 per share, with a total value of $2,300,881.00. Following the completion of the acquisition, the insider directly owned 1,297,893 shares of the company’s stock, valued at $14,419,591.23. This represents a 18.99% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Forest Baskett acquired 207,100 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were bought at an average cost of $11.11 per share, for a total transaction of $2,300,881.00. Following the completion of the acquisition, the insider directly owned 1,297,893 shares of the company’s stock, valued at approximately $14,419,591.23. The trade was a 18.99% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders bought 1,657,320 shares of company stock valued at $18,412,560. 4.80% of the stock is owned by corporate insiders.

Korro Bio News Roundup

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: Citigroup initiated coverage of Korro Bio with a Buy rating and a $21 price target, implying significant upside from recent trading levels. Citigroup initiates coverage of Korro Bio (KRRO) with buy recommendation
• Positive Sentiment: HC Wainwright reiterated a Buy rating on KRRO and maintained a $15 price target while publishing earnings estimates for 2027, signaling continued analyst support for the stock. Korro Bio price target lowered by HC Wainwright
• Positive Sentiment: Korro announced KRRO-111 as a development candidate for potential treatment of alpha-1 antitrypsin deficiency, with preclinical data showing strong editing and protein-repair results in a mouse model. Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
• Neutral Sentiment: Additional coverage described Korro Bio as one of the healthcare names analysts are currently bullish on, reinforcing a favorable sentiment backdrop. Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Korro Bio (KRRO)
• Neutral Sentiment: HC Wainwright also lowered its price target from $20 to $15, which tempers some of the enthusiasm even though the firm kept a Buy rating. Korro Bio price target lowered by HC Wainwright

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.